Despite the fact that the degree of ALT change was subtle (the median change was + 2 U/L), and there were no cases of severe hepatitis leading to hospitalization or mortality in our study, 44.5% of patients who took ADG had ALT elevation greater than 3 U/L, significantly higher than in patients without ADG (32.2%, p = 0.018). This evidence concerns the gene GPT and hepatitis A virus infection.